Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naurex Spinout Aptinyx Launches After Allergan Deal

This article was originally published in Scrip

Executive Summary

Work did not slow down at Naurex after its acquisition by Allergan for $560m up front – a return of at least 3.4 times the $163m in venture capital invested in the company – since the underlying technology platform was spun out in a new firm, which launched on Sept. 16 as Aptinyx.

Advertisement

Related Content

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
Aptinyx Cashes In Post-Naurex Cache With $65m Series A

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel